Catabasis Pharmaceuticals, Inc. (CATB) Analysts See $-0.34 EPS

February 15, 2018 - By Vivian Park

 Catabasis Pharmaceuticals, Inc. (CATB) Analysts See $ 0.34 EPS

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.34 EPS on March, 15.They anticipate $0.13 EPS change or 27.66 % from last quarter’s $-0.47 EPS. After having $-0.31 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see 9.68 % EPS growth. The stock increased 0.72% or $0.01 during the last trading session, reaching $1.4. About 1.06 million shares traded or 53.18% up from the average. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 73.74% since February 15, 2017 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Coverage

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. Citigroup maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Tuesday, March 22 with “Buy” rating. The rating was maintained by Wedbush with “Buy” on Monday, August 14. The rating was maintained by H.C. Wainwright on Monday, August 14 with “Buy”. H.C. Wainwright initiated Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rating on Thursday, December 22. H.C. Wainwright has “Buy” rating and $14 target. Wedbush maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Monday, August 17 with “Buy” rating. The firm has “Hold” rating by Cowen & Co given on Thursday, August 10. As per Wednesday, June 8, the company rating was maintained by Wedbush. Oppenheimer maintained the shares of CATB in report on Monday, August 14 with “Buy” rating. The rating was maintained by Citigroup on Thursday, October 5 with “Neutral”. Cowen & Co maintained the shares of CATB in report on Thursday, October 5 with “Hold” rating.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $32.32 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

More notable recent Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) news were published by: Seekingalpha.com which released: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q1 2017 Results – Earnings …” on May 12, 2017, also Businesswire.com with their article: “Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to …” published on October 04, 2017, Businesswire.com published: “Annual Piper Jaffray Healthcare Conference” on November 21, 2017. More interesting news about Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) were released by: Seekingalpha.com and their article: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q3 2017 Results – Earnings …” published on November 10, 2017 as well as Businesswire.com‘s news article titled: “Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and …” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: